Feromics: Redefining Discovery Through Functional Immunomics
Feromics, a cutting-edge biotechnology company based in Boston, is pioneering transformative breakthroughs in functional immunomics—a frontier science dedicated to uncovering key immune cell pathways that could revolutionize the next generation of immunotherapies for cancer and autoimmune diseases.
At the core of Feromics’ innovation is its proprietary Intelligent Design™ technology, which merges AI-driven bioinformatics with deep biological insights. This unique approach enables the identification of function-specific immune pathways that regulate cellular behaviors such as cancer cell killing, guiding the design of safer and more effective treatments.
A Mission Rooted in Precision and Personalization
Feromics' strategy focuses on precision, personalization, and innovation. By creating proprietary libraries of interacting disease and immune cells, the company’s AI-integrated analysis uncovers novel therapeutic targets that enhance CAR-T and CAR-Treg design, optimize donor cell selection for allogeneic immunotherapies, and streamline the transition from research to clinical application. Their approach tailors treatments to each patient’s immune profile—an essential step toward realizing the promise of personalized medicine.
Partnerships and Recognition
Feromics believes in the power of collaboration. Through strategic partnerships, they aim to empower discovery across the biotech and pharmaceutical landscape, expanding the reach and impact of immunotherapy innovation.
The company’s groundbreaking work has been recognized by the Advanced Research Projects Agency for Health (ARPA-H), which awarded Feromics a $4 million, three-year contract to develop precision medicine technologies that improve patient treatment selection in cancer immunotherapy. Supported under Contract No. 75N91024C00036, this initiative underscores Feromics’ growing influence in shaping the future of biomedical science.
The Founders Behind the Vision
Feromics was co-founded by Shai Schubert, Ph.D. and Tania Konry, Ph.D., whose collaboration traces back to Konry’s laboratory at Northeastern University. Beginning in 2013, their research team of engineers, biologists, and computer scientists developed the single-cell assay models that now drive Feromics’ technology.
Dr. Schubert, who serves as CEO, brings extensive experience in biotechnology and medical device innovation. His mission centers on developing transformative treatments for underserved patient populations, guided by a career that bridges scientific excellence and entrepreneurial leadership.
A Legacy of Innovation
From more than 52 scientific publications and patents to collaborations with major pharmaceutical companies, Feromics continues to build on a decade of rigorous research and discovery. With a vision to transform how immune pathways are understood and harnessed, the company is driving biomedical innovation from concept to clinic.
To learn more about Feromics and its groundbreaking work in functional immunomics, visit here.